DPP4i | Non-DPP4i | ||||||
---|---|---|---|---|---|---|---|
PS decile-stratified analysis | N=73 928 | N=163 062 | |||||
Cases | Person-years | IR† (95% CI) | Cases | Person-years | IR† (95% CI) | HR‡ (95% CI) | |
RA | 48 | 38 135 | 1.26 (0.93 to 1.67) | 131 | 80 020 | 1.64 (1.37 to 1.94) | 0.66 (0.44 to 0.99) |
Other AD | 68 | 38 120 | 1.78 (1.39 to 2.26) | 181 | 79 997 | 2.26 (1.94 to 2.62) | 0.73 (0.51 to 1.03) |
Composite AD | 114 | 38 103 | 2.99 (2.47 to 3.59) | 310 | 79 948 | 3.88 (3.46 to 4.33) | 0.68 (0.52 to 0.89) |
N=47 884 | N=47 884 | ||||||
PS-matched analysis | Cases | Person-years | IR† (95% CI) | Cases | Person-years | IR† (95% CI) | HR‡ (95% CI) |
RA | 28 | 24 171 | 1.16 (0.77 to 1.67) | 40 | 23 979 | 1.67 (1.19 to 2.27) | 0.70 (0.43 to 1.13) |
Other AD | 38 | 24 164 | 1.57 (1.11 to 2.16) | 46 | 23 975 | 1.92 (1.40 to 2.56) | 0.82 (0.53 to 1.26) |
Composite AD | 65 | 24 154 | 2.69 (2.08 to 3.43) | 86 | 23 959 | 3.59 (2.87 to 4.43) | 0.75 (0.54 to 1.04) |
The logistic model for PS includes age, sex, comorbidities, smoking, obesity, non-diabetic medications, number of oral diabetic meds, number of primary and specialist visits, and other healthcare use.
*As treated analysis censoring at discontinuation or switching of study drugs, loss of health plan eligibility, end of study database, death or 365 days, whichever came first.
†Per 1000 person-years.
‡Non-DPP4i as a referent group.
AD, autoimmune disease; DPP4i, dipeptidyl peptidase-4 inhibitor; IR, incidence rate; PS, propensity score; RA, rheumatoid arthritis.